You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
NEW YORK (GenomeWeb News) – French firm Cellectis and North Carolina-based Precision Biosciences have filed two new suits against each other alleging infringement of US patents covering modified meganucleases.
Helix will promote Cellectis' Genome Positioning System line of products and services in India.
The French firm gains access to Cyto Pulse's electroporation technologies and equipment.
Cedarlane will distribute Cellectis Bioresearch's kits in Canada.
The patent has been the subject of ongoing litigation between the French and US biotech firms.
The agricultural products company will use Cellectis' meganuclease tools and will invest in the French firm.
Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.
The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.
Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.
This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.